Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperbaric Oxygen Therapy in Multiple Myeloma Patients Undergoing Stem Cell Transplantation
NCT04862676Phase 1Completed
- Sponsor
- University of Rochester
- Start
- Apr 2022
- Primary completion
- Apr 2025
- Modality
- NPI (Non-Pharmacological Intervention)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hyperbaric oxygen therapy in multiple myeloma (MM), sponsored by University of Rochester. Primary endpoints: Number of participants with a treatment-limiting toxicity at 24 hours and Number of participants with an AE or SAE attributed to HBO therapy at 100 days. Started Apr 2022; status: completed.
02
Drugs
hyperbaric oxygen therapy
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04862676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04862676.